Aberrant TRPM4 expression in MLL-rearranged acute myeloid leukemia and its blockade induces cell cycle arrest via AKT/GLI1/Cyclin D1 pathway

Fujue Wang,Pengqiang Wu,Shuaige Gong,Yingying Chen,Jie Gao,Shuoting Wang,Qianqing Shen,Huan Tao,Fang Hua,ZhenCang Zhou,Zhongqing Zou,Tao Ma,Yongqian Jia
DOI: https://doi.org/10.1016/j.cellsig.2020.109643
IF: 4.85
2020-08-01
Cellular Signalling
Abstract:<p>Transient Receptor Potential Melastatin Subfamily Member 4 (<em>TRPM4</em>) has been demonstrated to be aberrantly expressed in several cancers but seldom reported in acute leukemia. Based on database mining and validated experiments, our present data show that <em>TRPM4</em> is selectively overexpressed in AML patients and cell lines with the <em>MLL</em> gene rearrangement. We analyzed the correlation between <em>TRPM4</em> expression and clinical parameters in a validated cohort of AML patients. Increased <em>TRPM4</em> expression was associated with significant leukocytosis (<em>p</em> = .028), M4/M5 subtype (<em>p</em> = .000), <em>FLT3-ITD</em> mutation (<em>p</em> = .034), <em>MLL</em> status (<em>p</em> = .007) and a higher risk stratification (<em>p</em> = .001). Knockdown of <em>TRPM4</em> mediated by siRNA impaired proliferation and arrested the cell cycle at the G0/G1 phase in <em>MLL</em>-rearranged leukemia cells. We suggested that <em>TRPM4</em> may be involved in the pathogenesis of <em>MLL</em>-rearranged leukemia through regulating the AKT/GLI1/Cyclin D1 pathway. The transcription factor <em>HOXA9</em> was found to be responsible for upregulation of <em>TRPM4</em> expression by binding to its promoter. In conclusion, <em>TRPM4</em> is overexpressed in <em>MLL</em>-rearranged AML and blockade of <em>TRPM4</em> may be an alternative therapeutic approach in AML patients with high <em>TRPM4</em> expression.</p>
cell biology
What problem does this paper attempt to address?